DT
Therapeutic Areas
Circio Pipeline
| Drug | Indication | Phase |
|---|---|---|
| circVec (AAV-circVec) | Rare Disease (Genetic Medicine) | Discovery |
| circVec | Cancer Gene Therapy | Discovery |
| TG01 / QS-21 +/- anti-PD-1 | Pancreatic Cancer & Multiple Myeloma | Phase 1/2 |
Leadership Team at Circio
DE
Dr Erik Digman Wiklund
Chief Executive Officer
DV
Dr Victor Levitsky
Chief Scientific Officer
DL
Dr Lubor Gaal
Chief Financial Officer
DM
Damian Marron
Chairman of the Board
DM
Diane Mellett
Board Member
RB
Robert Burns
Deputy Board Member
TF
Thomas Falck
Board Member